

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information**  
**Full Analysis Dataset : ASIA**

Number of prospective patients (C1+C2+C3+C4+C5 )	14713
Number of enrolling sites	446
Number of enrolling countries	8
Enrolment period	10MAY2010 - 27JUL2016
Duration of enrolment (months)	74.6

**Table 02: Patients by region, country, and cohort  
Full Analysis Dataset : ASIA**

Region	Country	Cohort 1 Retrospective patients (N=1001)	Cohort 1 Prospective patients (N=1581)	Cohort 2 (N=2357)	Cohort 3 (N=3206)	Cohort 4 (N=3973)	Cohort 5 (N=3596)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Asia		1001	1581	2357	3206	3973	3596	14713	11117
	China	305	495	444	504	530	487	2460	1973
	India	0	0	317	334	241	420	1312	892
	Japan	149	248	579	1119	1774	1138	4858	3720
	Korea	547	838	757	590	490	523	3198	2675
	Singapore	0	0	70	71	62	99	302	203
	Thailand	0	0	190	456	415	433	1494	1061
	Turkey	0	0	0	0	318	395	713	318
	United Arab Emirates	0	0	0	132	143	101	376	275

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Sex, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Male	637 (63.6)	964 (61.0)	1417 (60.1)	1853 (57.8)	2326 (58.5)	2112 (58.7)	8672 (58.9)	6560 (59.0)
	Female	364 (36.4)	617 (39.0)	940 (39.9)	1353 (42.2)	1647 (41.5)	1484 (41.3)	6041 (41.1)	4557 (41.0)
Age at Diagnosis (Years)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Mean (SD)	65.2 (11.0)	66.0 (11.9)	67.1 (11.8)	67.6 (11.8)	68.0 (12.3)	68.1 (12.3)	67.6 (12.1)	67.4 (12.0)
	Median (IQR)	66.0 (58.0 to 73.0)	68.0 (58.0 to 74.0)	69.0 (59.0 to 76.0)	69.0 (60.0 to 76.0)	69.0 (60.0 to 77.0)	69.0 (60.0 to 77.0)	69.0 (60.0 to 76.0)	69.0 (60.0 to 76.0)
	Min to Max	27 to 99	18 to 99	23 to 99	19 to 97	19 to 105	19 to 101	18 to 105	18 to 105
Age Group, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	<65	428 (42.8)	631 (39.9)	902 (38.3)	1168 (36.4)	1406 (35.4)	1296 (36.0)	5403 (36.7)	4107 (36.9)
	65-74	361 (36.1)	563 (35.6)	765 (32.5)	1055 (32.9)	1324 (33.3)	1121 (31.2)	4828 (32.8)	3707 (33.3)
	>=75	212 (21.2)	387 (24.5)	690 (29.3)	983 (30.7)	1243 (31.3)	1179 (32.8)	4482 (30.5)	3303 (29.7)
Time since AF Diagnosis (Weeks)	n (missing)	1001 (0)	1224 (357)	1623 (734)	1997 (1209)	2236 (1737)	2016 (1580)	9096 (5617)	7080 (4037)
	Mean (SD)	58.96 (23.54)	2.24 (1.69)	2.01 (1.60)	1.92 (1.64)	1.92 (1.68)	1.86 (1.60)	1.97 (1.64)	2.00 (1.66)
	Median (IQR)	55.40 (38.00 to 78.70)	1.80 (0.80 to 3.50)	1.70 (0.70 to 3.10)	1.40 (0.50 to 3.00)	1.40 (0.50 to 3.00)	1.40 (0.50 to 3.00)	1.50 (0.50 to 3.10)	1.50 (0.70 to 3.10)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 14.2	0.1 to 6.0	0.1 to 14.2	0.1 to 14.2
Race, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3971 (0)	3593 (0)	14708 (0)	11115 (0)
	Caucasian	-	-	2 (0.1)	23 (0.7)	234 (5.9)	318 (8.9)	577 (3.9)	259 (2.3)
	Afro-Caribbean	-	-	-	1 (0.0)	5 (0.1)	4 (0.1)	10 (0.1)	6 (0.1)
	Asian (Not Chinese)	699 (69.8)	1089 (68.9)	1871 (79.4)	2605 (81.3)	3107 (78.2)	2621 (72.9)	11293 (76.8)	8672 (78.0)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	Chinese	302 (30.2)	491 (31.1)	483 (20.5)	559 (17.4)	571 (14.4)	569 (15.8)	2673 (18.2)	2104 (18.9)
	Mixed/Other	-	1 (0.1)	1 (0.0)	18 (0.6)	54 (1.4)	81 (2.3)	155 (1.1)	74 (0.7)
	Unknown	-	-	-	-	2	3	5	2
Region, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Asia	1001 (100.0)	1581 (100.0)	2357 (100.0)	3206 (100.0)	3973 (100.0)	3596 (100.0)	14713 (100.0)	11117 (100.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Internal Medicine	142 (14.2)	205 (13.0)	214 (9.1)	288 (9.0)	519 (13.1)	421 (11.7)	1647 (11.2)	1226 (11.0)
	Cardiology	804 (80.3)	1308 (82.7)	2011 (85.3)	2764 (86.2)	3325 (83.7)	3045 (84.7)	12453 (84.6)	9408 (84.6)
	Neurology	9 (0.9)	14 (0.9)	20 (0.8)	30 (0.9)	40 (1.0)	27 (0.8)	131 (0.9)	104 (0.9)
	Geriatrics	-	3 (0.2)	7 (0.3)	5 (0.2)	10 (0.3)	6 (0.2)	31 (0.2)	25 (0.2)
	Primary Care/General Practice	46 (4.6)	51 (3.2)	105 (4.5)	119 (3.7)	79 (2.0)	97 (2.7)	451 (3.1)	354 (3.2)
Care Setting Location at Diagnosis, n(%)	n (missing)	999 (1)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Hospital	951 (95.2)	1521 (96.2)	2268 (96.2)	2216 (69.1)	2421 (60.9)	2409 (67.0)	10835 (73.6)	8426 (75.8)
	Office	13 (1.3)	8 (0.5)	37 (1.6)	878 (27.4)	1407 (35.4)	1079 (30.0)	3409 (23.2)	2330 (21.0)
	Anticoagulation clinic/thrombosi s centre	1 (0.1)	2 (0.1)	4 (0.2)	3 (0.1)	5 (0.1)	3 (0.1)	17 (0.1)	14 (0.1)
	Emergency room	34 (3.4)	50 (3.2)	48 (2.0)	109 (3.4)	140 (3.5)	105 (2.9)	452 (3.1)	347 (3.1)
	Unknown	1	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	Permanent	258 (25.8)	129 (8.2)	118 (5.0)	259 (8.1)	360 (9.1)	388 (10.8)	1254 (8.5)	866 (7.8)
	Persistent	293 (29.3)	267 (16.9)	499 (21.2)	583 (18.2)	659 (16.6)	563 (15.7)	2571 (17.5)	2008 (18.1)
	Paroxysmal	366 (36.6)	439 (27.8)	837 (35.5)	1266 (39.5)	1591 (40.0)	1238 (34.4)	5371 (36.5)	4133 (37.2)
	New	84 (8.4)	746 (47.2)	903 (38.3)	1098 (34.2)	1363 (34.3)	1407 (39.1)	5517 (37.5)	4110 (37.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Treatment Costs, n(%)	n (missing)	-	12 (0)	1754 (0)	2737 (0)	3580 (0)	3224 (0)	11307 (0)	8083 (0)
	Public insurance	-	12 (100.0)	1335 (76.1)	2181 (79.7)	2888 (80.7)	2508 (77.8)	8924 (78.9)	6416 (79.4)
	Private (insurance)	-	-	48 (2.7)	57 (2.1)	141 (3.9)	100 (3.1)	346 (3.1)	246 (3.0)
	Private (out of pocke	-	-	225 (12.8)	304 (11.1)	252 (7.0)	295 (9.2)	1076 (9.5)	781 (9.7)
	Combination Unknown	-	-	146 (8.3) 603	195 (7.1) 469	299 (8.4) 393	321 (10.0) 372	961 (8.5) 3406	640 (7.9) 3034
Treatment Sector, n(%)	n (missing)	1 (0)	19 (0)	1936 (0)	3110 (0)	3916 (0)	3543 (0)	12524 (0)	8981 (0)
	In the public sector	-	6 (31.6)	877 (45.3)	1517 (48.8)	1790 (45.7)	1701 (48.0)	5891 (47.0)	4190 (46.7)
	In the private sector	1 (100.0)	13 (68.4)	1059 (54.7)	1593 (51.2)	2126 (54.3)	1842 (52.0)	6633 (53.0)	4791 (53.3)
	Unknown	1000	1562	421	96	57	53	2189	2136

**Table 05 : Vital signs and life style**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Height (cm)	n (missing)	837 (164)	1396 (185)	1903 (454)	2602 (604)	3167 (806)	2867 (729)	11935 (2778)	9068 (2049)
	Mean (SD)	164.3 (9.2)	163.7 (9.1)	162.5 (9.6)	161.9 (9.9)	162.1 (9.9)	162.5 (9.9)	162.4 (9.8)	162.4 (9.7)
	Median (IQR)	165.0 (158.0 to 171.0)	165.0 (157.0 to 170.0)	163.0 (156.0 to 170.0)	162.0 (155.0 to 170.0)	162.0 (155.0 to 170.0)	163.0 (155.0 to 170.0)	163.0 (155.0 to 170.0)	163.0 (155.0 to 170.0)
	Min to Max	138 to 187	130 to 190	129 to 190	121 to 191	127 to 197	126 to 198	121 to 198	121 to 197
Weight (kg)	n (missing)	837 (164)	1396 (185)	1903 (454)	2602 (604)	3167 (806)	2867 (729)	11935 (2778)	9068 (2049)
	Mean (SD)	66.7 (12.4)	65.5 (11.8)	65.0 (12.4)	65.1 (14.4)	66.0 (14.5)	66.2 (14.5)	65.6 (13.9)	65.4 (13.7)
	Median (IQR)	67.0 (58.0 to 74.0)	65.0 (57.0 to 73.0)	65.0 (57.0 to 73.0)	65.0 (55.0 to 73.0)	65.0 (56.0 to 74.0)	65.0 (56.0 to 75.0)	65.0 (56.0 to 74.0)	65.0 (56.0 to 74.0)
	Min to Max	35 to 115	30 to 108	29 to 131	31 to 166	30 to 150	31 to 138	29 to 166	29 to 166
BMI (kg/m <sup>2</sup> )	n (missing)	837 (164)	1396 (185)	1903 (454)	2602 (604)	3167 (806)	2867 (729)	11935 (2778)	9068 (2049)
	Mean (SD)	24.6 (3.4)	24.4 (3.3)	24.5 (3.6)	24.7 (4.4)	25.0 (4.5)	25.0 (4.5)	24.8 (4.2)	24.7 (4.1)
	Median (IQR)	24.0 (22.0 to 27.0)	24.0 (22.0 to 26.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)	24.0 (22.0 to 27.0)
	Min to Max	14 to 42	12 to 39	14 to 41	13 to 49	12 to 57	12 to 51	12 to 57	12 to 57
BMI Category, n(%)	n (missing)	837 (164)	1396 (185)	1903 (454)	2602 (604)	3167 (806)	2867 (729)	11935 (2778)	9068 (2049)
	<19	38 (4.5)	60 (4.3)	112 (5.9)	177 (6.8)	175 (5.5)	155 (5.4)	679 (5.7)	524 (5.8)
	19-<25	439 (52.4)	767 (54.9)	975 (51.2)	1299 (49.9)	1596 (50.4)	1454 (50.7)	6091 (51.0)	4637 (51.1)
	25-<30	308 (36.8)	502 (36.0)	677 (35.6)	851 (32.7)	1042 (32.9)	944 (32.9)	4016 (33.6)	3072 (33.9)
	30-<40	51 (6.1)	67 (4.8)	138 (7.3)	258 (9.9)	328 (10.4)	279 (9.7)	1070 (9.0)	791 (8.7)
	>=40	1 (0.1)	-	1 (0.1)	17 (0.7)	26 (0.8)	35 (1.2)	79 (0.7)	44 (0.5)
Pulse (bpm)	n (missing)	814 (187)	1377 (204)	2151 (206)	2993 (213)	3725 (248)	3409 (187)	13655 (1058)	10246 (871)
	Mean (SD)	82.8 (21.0)	86.2 (23.7)	86.3 (23.8)	88.0 (23.6)	87.5 (24.3)	88.7 (24.4)	87.6 (24.1)	87.2 (23.9)
	Median (IQR)	79.0 (69.0 to 92.0)	81.0 (70.0 to 98.0)	81.0 (70.0 to 97.0)	84.0 (71.0 to 100.0)	82.0 (70.0 to 100.0)	84.0 (72.0 to 100.0)	82.0 (70.0 to 100.0)	82.0 (70.0 to 99.0)
	Min to Max	45 to 179	34 to 203	33 to 196	40 to 187	36 to 200	29 to 210	29 to 210	33 to 203

**Table 05 : Vital signs and life style  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Systolic BP (mm Hg)	n (missing)	896 (105)	1489 (92)	2252 (105)	3106 (100)	3816 (157)	3455 (141)	14118 (595)	10663 (454)
	Mean (SD)	128.0 (19.8)	127.6 (19.8)	128.9 (19.5)	129.5 (19.9)	129.9 (18.8)	129.1 (19.3)	129.2 (19.4)	129.2 (19.4)
	Median (IQR)	130.0 (116.5 to 140.0)	129.0 (115.0 to 140.0)	129.5 (116.0 to 140.0)	130.0 (117.0 to 140.0)	130.0 (119.0 to 140.0)	130.0 (117.0 to 140.0)	130.0 (117.0 to 140.0)	130.0 (117.0 to 140.0)
	Min to Max	60 to 220	50 to 206	70 to 230	60 to 254	68 to 215	55 to 240	50 to 254	50 to 254
Diastolic BP (mm Hg)	n (missing)	896 (105)	1489 (92)	2252 (105)	3106 (100)	3816 (157)	3455 (141)	14118 (595)	10663 (454)
	Mean (SD)	78.7 (12.9)	78.6 (14.1)	78.0 (13.0)	77.7 (14.0)	77.4 (13.4)	77.4 (13.1)	77.7 (13.5)	77.8 (13.6)
	Median (IQR)	80.0 (70.0 to 85.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 86.0)	78.0 (70.0 to 86.0)	77.0 (70.0 to 85.0)	78.0 (70.0 to 86.0)	78.0 (70.0 to 86.0)	78.0 (70.0 to 86.0)
	Min to Max	40 to 149	40 to 164	34 to 140	27 to 159	29 to 150	35 to 146	27 to 164	27 to 164
LVEF (%)	n (missing)	696 (305)	1210 (371)	1517 (840)	2201 (1005)	2795 (1178)	2374 (1222)	10097 (4616)	7723 (3394)
	Mean (SD)	59.0 (12.1)	58.3 (11.8)	58.4 (13.2)	58.9 (13.1)	59.4 (12.5)	57.3 (13.2)	58.5 (12.8)	58.9 (12.7)
	Median (IQR)	61.0 (54.0 to 67.0)	60.0 (53.0 to 66.0)	60.0 (54.0 to 67.0)	61.0 (54.0 to 67.0)	61.0 (55.0 to 68.0)	60.0 (51.0 to 66.0)	60.0 (53.0 to 67.0)	61.0 (54.0 to 67.0)
	Min to Max	11 to 85	17 to 84	15 to 91	12 to 93	10 to 90	11 to 90	10 to 93	10 to 93
LVEF Category, n (missing) n(%)	n (missing)	696 (305)	1210 (371)	1517 (840)	2201 (1005)	2795 (1178)	2374 (1222)	10097 (4616)	7723 (3394)
	<40%	58 (8.3)	99 (8.2)	152 (10.0)	206 (9.4)	222 (7.9)	277 (11.7)	956 (9.5)	679 (8.8)
	>=40%	638 (91.7)	1111 (91.8)	1365 (90.0)	1995 (90.6)	2573 (92.1)	2097 (88.3)	9141 (90.5)	7044 (91.2)
History of Hypertension, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3187 (0)	3949 (0)	3579 (0)	14653 (0)	11074 (0)
	No	288 (28.8)	537 (34.0)	687 (29.1)	985 (30.9)	1292 (32.7)	1191 (33.3)	4692 (32.0)	3501 (31.6)
	Yes	713 (71.2)	1044 (66.0)	1670 (70.9)	2202 (69.1)	2657 (67.3)	2388 (66.7)	9961 (68.0)	7573 (68.4)

**Table 05 : Vital signs and life style**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	Unknown	-	-	-	19	24	17	60	43
Alcohol Consumption, n(%)	n (missing)	934 (0)	1469 (0)	2008 (0)	2647 (0)	3365 (1)	2939 (0)	12428 (1)	9489 (1)
	Abstinent	619 (66.3)	967 (65.8)	1403 (69.9)	1782 (67.3)	2228 (66.2)	2038 (69.3)	8418 (67.7)	6380 (67.2)
	Light	181 (19.4)	316 (21.5)	300 (14.9)	500 (18.9)	742 (22.1)	539 (18.3)	2397 (19.3)	1858 (19.6)
	Moderate	92 (9.9)	119 (8.1)	217 (10.8)	291 (11.0)	317 (9.4)	300 (10.2)	1244 (10.0)	944 (9.9)
	Heavy	42 (4.5)	67 (4.6)	88 (4.4)	74 (2.8)	78 (2.3)	62 (2.1)	369 (3.0)	307 (3.2)
	Unknown	67	112	349	559	607	657	2284	1627
Smoker, n(%)	n (missing)	938 (0)	1496 (0)	2075 (0)	2846 (0)	3586 (0)	3153 (0)	13156 (0)	10003 (0)
	No	610 (65.0)	990 (66.2)	1454 (70.1)	1987 (69.8)	2467 (68.8)	2226 (70.6)	9124 (69.4)	6898 (69.0)
	Ex-smoker	190 (20.3)	273 (18.2)	360 (17.3)	487 (17.1)	706 (19.7)	549 (17.4)	2375 (18.1)	1826 (18.3)
	Current smoker	138 (14.7)	233 (15.6)	261 (12.6)	372 (13.1)	413 (11.5)	378 (12.0)	1657 (12.6)	1279 (12.8)
	Unknown	63	85	282	360	387	443	1557	1114

**Table 06 : Clinical History**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Congestive heart failure, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	No	806 (80.5)	1295 (81.9)	1879 (79.7)	2549 (79.5)	3139 (79.0)	2903 (80.7)	11765 (80.0)	8862 (79.7)
	Yes	195 (19.5)	286 (18.1)	478 (20.3)	657 (20.5)	834 (21.0)	693 (19.3)	2948 (20.0)	2255 (20.3)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	188 (806)	278 (1295)	433 (1879)	602 (2549)	745 (3139)	589 (2903)	2647 (11765)	2058 (8862)
	I	38 (20.2)	69 (24.8)	134 (30.9)	219 (36.4)	245 (32.9)	164 (27.8)	831 (31.4)	667 (32.4)
	II	80 (42.6)	119 (42.8)	179 (41.3)	227 (37.7)	309 (41.5)	258 (43.8)	1092 (41.3)	834 (40.5)
	III	50 (26.6)	66 (23.7)	82 (18.9)	114 (18.9)	157 (21.1)	131 (22.2)	550 (20.8)	419 (20.4)
	IV	20 (10.6)	24 (8.6)	38 (8.8)	42 (7.0)	34 (4.6)	36 (6.1)	174 (6.6)	138 (6.7)
	Unknown	7	8	45	55	89	104	301	197
Coronary artery disease, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	No	808 (80.7)	1302 (82.4)	1959 (83.1)	2671 (83.3)	3243 (81.6)	2876 (80.0)	12051 (81.9)	9175 (82.5)
	Yes	193 (19.3)	279 (17.6)	398 (16.9)	535 (16.7)	730 (18.4)	720 (20.0)	2662 (18.1)	1942 (17.5)
Acute coronary syndrome, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3188 (0)	3938 (0)	3551 (0)	14615 (0)	11064 (0)
	No	927 (92.6)	1469 (92.9)	2182 (92.6)	2981 (93.5)	3640 (92.4)	3269 (92.1)	13541 (92.7)	10272 (92.8)
	Yes	74 (7.4)	112 (7.1)	175 (7.4)	207 (6.5)	298 (7.6)	282 (7.9)	1074 (7.3)	792 (7.2)
	Unknown	-	-	-	18	35	45	98	53
Carotid Occlusive Disease, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3154 (0)	3877 (0)	3482 (0)	14451 (0)	10969 (0)
	No	989 (98.8)	1567 (99.1)	2332 (98.9)	3075 (97.5)	3804 (98.1)	3406 (97.8)	14184 (98.2)	10778 (98.3)

**Table 06 : Clinical History**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	Yes	12 (1.2)	14 (0.9)	25 (1.1)	79 (2.5)	73 (1.9)	76 (2.2)	267 (1.8)	191 (1.7)
	Unknown	-	-	-	52	96	114	262	148
PE or DVT, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3169 (0)	3944 (0)	3530 (0)	14581 (0)	11051 (0)
	No	994 (99.3)	1576 (99.7)	2344 (99.4)	3147 (99.3)	3921 (99.4)	3500 (99.2)	14488 (99.4)	10988 (99.4)
	Yes	7 (0.7)	5 (0.3)	13 (0.6)	22 (0.7)	23 (0.6)	30 (0.8)	93 (0.6)	63 (0.6)
	Unknown	-	-	-	37	29	66	132	66
Other Thromboemboli sm, n(%)	n (missing)	1001 (0)	1581 (0)	2331 (26)	0 (3206)	0 (3973)	0 (3596)	3912 (10801)	3912 (7205)
	No	997 (99.6)	1573 (99.5)	2322 (99.6)	-	-	-	3895 (99.6)	3895 (99.6)
	Yes	4 (0.4)	8 (0.5)	9 (0.4)	-	-	-	17 (0.4)	17 (0.4)
Systemic Embolization, n(%)	n (missing)	1001 (0)	1581 (0)	2356 (0)	3170 (0)	3940 (0)	3532 (0)	14579 (0)	11047 (0)
	No	996 (99.5)	1575 (99.6)	2349 (99.7)	3154 (99.5)	3924 (99.6)	3516 (99.5)	14518 (99.6)	11002 (99.6)
	Yes	5 (0.5)	6 (0.4)	7 (0.3)	16 (0.5)	16 (0.4)	16 (0.5)	61 (0.4)	45 (0.4)
	Unknown	-	-	1	36	33	64	134	70
Coronary Artery Bypass Graft, n(%)	n (missing)	940 (0)	1507 (0)	2357 (0)	3176 (0)	3954 (0)	3555 (0)	14549 (0)	10994 (0)
	No	938 (99.8)	1502 (99.7)	2325 (98.6)	3127 (98.5)	3889 (98.4)	3457 (97.2)	14300 (98.3)	10843 (98.6)
	Yes	2 (0.2)	5 (0.3)	32 (1.4)	49 (1.5)	65 (1.6)	98 (2.8)	249 (1.7)	151 (1.4)
	Unknown	61	74	-	30	19	41	164	123
Stroke/TIA, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)

**Table 06 : Clinical History**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	No	857 (85.6)	1409 (89.1)	2070 (87.8)	2879 (89.8)	3556 (89.5)	3208 (89.2)	13122 (89.2)	9914 (89.2)
	Yes	144 (14.4)	172 (10.9)	287 (12.2)	327 (10.2)	417 (10.5)	388 (10.8)	1591 (10.8)	1203 (10.8)
Stroke, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3167 (0)	3946 (0)	3546 (0)	14597 (0)	11051 (0)
	No	888 (88.7)	1447 (91.5)	2108 (89.4)	2933 (92.6)	3618 (91.7)	3273 (92.3)	13379 (91.7)	10106 (91.4)
	Yes	113 (11.3)	134 (8.5)	249 (10.6)	234 (7.4)	328 (8.3)	273 (7.7)	1218 (8.3)	945 (8.6)
	Unknown	-	-	-	39	27	50	116	66
History of Bleeding, n(%)	n (missing)	1001 (0)	1581 (0)	2356 (0)	3165 (0)	3943 (0)	3544 (0)	14589 (0)	11045 (0)
	No	981 (98.0)	1540 (97.4)	2319 (98.4)	3120 (98.6)	3875 (98.3)	3490 (98.5)	14344 (98.3)	10854 (98.3)
	Yes	20 (2.0)	41 (2.6)	37 (1.6)	45 (1.4)	68 (1.7)	54 (1.5)	245 (1.7)	191 (1.7)
	Unknown	-	-	1	41	30	52	124	72
Hypercholester olaemia, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3107 (0)	3841 (0)	3482 (0)	14368 (0)	10886 (0)
	No	793 (79.2)	1286 (81.3)	1758 (74.6)	2172 (69.9)	2630 (68.5)	2402 (69.0)	10248 (71.3)	7846 (72.1)
	Yes	208 (20.8)	295 (18.7)	599 (25.4)	935 (30.1)	1211 (31.5)	1080 (31.0)	4120 (28.7)	3040 (27.9)
	Unknown	-	-	-	99	132	114	345	231
Diabetes, n(%)	n (missing)	1000 (1)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	No	802 (80.2)	1275 (80.6)	1829 (77.6)	2485 (77.5)	3116 (78.4)	2761 (76.8)	11466 (77.9)	8705 (78.3)
	Type I	11 (1.1)	21 (1.3)	11 (0.5)	47 (1.5)	41 (1.0)	38 (1.1)	158 (1.1)	120 (1.1)
	Type II	187 (18.7)	285 (18.0)	517 (21.9)	674 (21.0)	816 (20.5)	797 (22.2)	3089 (21.0)	2292 (20.6)
Diabetes, n(%)	n (missing)	1000 (1)	1581 (0)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14713 (0)	11117 (0)
	No	802 (80.2)	1275 (80.6)	1829 (77.6)	2485 (77.5)	3116 (78.4)	2761 (76.8)	11466 (77.9)	8705 (78.3)
	Yes	198 (19.8)	306 (19.4)	528 (22.4)	721 (22.5)	857 (21.6)	835 (23.2)	3247 (22.1)	2412 (21.7)
Cirrhosis, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3130 (0)	3904 (0)	3515 (0)	14487 (0)	10972 (0)
	No	998 (99.7)	1565 (99.0)	2347 (99.6)	3115 (99.5)	3874 (99.2)	3486 (99.2)	14387 (99.3)	10901 (99.4)

**Table 06 : Clinical History**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	Yes	3 (0.3)	16 (1.0)	10 (0.4)	15 (0.5)	30 (0.8)	29 (0.8)	100 (0.7)	71 (0.6)
	Unknown	-	-	-	76	69	81	226	145
Dementia, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3149 (0)	3938 (0)	3558 (0)	14583 (0)	11025 (0)
	No	991 (99.0)	1575 (99.6)	2318 (98.3)	3102 (98.5)	3841 (97.5)	3489 (98.1)	14325 (98.2)	10836 (98.3)
	Yes	10 (1.0)	6 (0.4)	39 (1.7)	47 (1.5)	97 (2.5)	69 (1.9)	258 (1.8)	189 (1.7)
	Unknown	-	-	-	57	35	38	130	92
Hyperthyroidis m, n(%)	n (missing)	1001 (0)	1581 (0)	2356 (0)	3102 (0)	3836 (0)	3476 (0)	14351 (0)	10875 (0)
	No	977 (97.6)	1543 (97.6)	2313 (98.2)	3052 (98.4)	3757 (97.9)	3389 (97.5)	14054 (97.9)	10665 (98.1)
	Yes	24 (2.4)	38 (2.4)	43 (1.8)	50 (1.6)	79 (2.1)	87 (2.5)	297 (2.1)	210 (1.9)
	Unknown	-	-	1	104	137	120	362	242
Hypothyroidism, n (missing) n(%)	n (missing)	1001 (0)	1581 (0)	2356 (0)	3102 (0)	3836 (0)	3474 (1)	14349 (1)	10875 (0)
	No	989 (98.8)	1559 (98.6)	2301 (97.7)	3022 (97.4)	3735 (97.4)	3371 (97.0)	13988 (97.5)	10617 (97.6)
	Yes	12 (1.2)	22 (1.4)	55 (2.3)	80 (2.6)	101 (2.6)	103 (3.0)	361 (2.5)	258 (2.4)
	Unknown	-	-	1	104	137	121	363	242
Vascular Disease, n(%)	n (missing)	1001 (0)	1581 (0)	2357 (0)	3194 (12)	3952 (21)	3557 (39)	14641 (72)	11084 (33)
	No	897 (89.6)	1443 (91.3)	2109 (89.5)	2825 (88.4)	3453 (87.4)	3100 (87.2)	12930 (88.3)	9830 (88.7)
	Yes	104 (10.4)	138 (8.7)	248 (10.5)	369 (11.6)	499 (12.6)	457 (12.8)	1711 (11.7)	1254 (11.3)
Moderate to Severe CKD, n(%)	n (missing)	1001 (0)	1580 (1)	2357 (0)	3206 (0)	3973 (0)	3596 (0)	14712 (1)	11116 (1)
	No	932 (93.1)	1490 (94.3)	2168 (92.0)	2957 (92.2)	3659 (92.1)	3324 (92.4)	13598 (92.4)	10274 (92.4)
	Yes	69 (6.9)	90 (5.7)	189 (8.0)	249 (7.8)	314 (7.9)	272 (7.6)	1114 (7.6)	842 (7.6)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

**Table 06 : Clinical History**  
**Full Analysis Dataset : ASIA**

**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
Baseline Treatment, n(%)	n (missing)	977 (0)	1546 (0)	2351 (0)	3194 (0)	3904 (0)	3551 (0)	14546 (0)	10995 (0)
	VKA	296 (30.3)	392 (25.4)	607 (25.8)	738 (23.1)	782 (20.0)	530 (14.9)	3049 (21.0)	2519 (22.9)
	VKA+AP	128 (13.1)	173 (11.2)	286 (12.2)	289 (9.0)	277 (7.1)	238 (6.7)	1263 (8.7)	1025 (9.3)
	FXA	-	2 (0.1)	81 (3.4)	483 (15.1)	1012 (25.9)	909 (25.6)	2487 (17.1)	1578 (14.4)
	FXA+AP	4 (0.4)	14 (0.9)	21 (0.9)	68 (2.1)	188 (4.8)	174 (4.9)	465 (3.2)	291 (2.6)
	DTI	-	17 (1.1)	137 (5.8)	193 (6.0)	207 (5.3)	237 (6.7)	791 (5.4)	554 (5.0)
	DTI+AP	6 (0.6)	22 (1.4)	26 (1.1)	41 (1.3)	51 (1.3)	39 (1.1)	179 (1.2)	140 (1.3)
	AP	394 (40.3)	650 (42.0)	824 (35.0)	850 (26.6)	786 (20.1)	817 (23.0)	3927 (27.0)	3110 (28.3)
	NONE	149 (15.3)	276 (17.9)	369 (15.7)	532 (16.7)	601 (15.4)	607 (17.1)	2385 (16.4)	1778 (16.2)
	Unknown	24	35	6	12	69	45	167	122
	VKA±AP	424 (43.4)	565 (36.5)	893 (38.0)	1027 (32.2)	1059 (27.1)	768 (21.6)	4312 (29.6)	3544 (32.2)
	FXA±AP	4 (0.4)	16 (1.0)	102 (4.3)	551 (17.3)	1200 (30.7)	1083 (30.5)	2952 (20.3)	1869 (17.0)
	DTI±AP	6 (0.6)	39 (2.5)	163 (6.9)	234 (7.3)	258 (6.6)	276 (7.8)	970 (6.7)	694 (6.3)
	FXA/DTI	-	19 (1.2)	218 (9.3)	676 (21.2)	1219 (31.2)	1146 (32.3)	3278 (22.5)	2132 (19.4)
	FXA/DTI+AP	10 (1.0)	36 (2.3)	47 (2.0)	109 (3.4)	239 (6.1)	213 (6.0)	644 (4.4)	431 (3.9)
	FXA/DTI±AP	10 (1.0)	55 (3.6)	265 (11.3)	785 (24.6)	1458 (37.3)	1359 (38.3)	3922 (27.0)	2563 (23.3)
	AC	296 (30.3)	411 (26.6)	825 (35.1)	1414 (44.3)	2001 (51.3)	1676 (47.2)	6327 (43.5)	4651 (42.3)
	AC+AP	138 (14.1)	209 (13.5)	333 (14.2)	398 (12.5)	516 (13.2)	451 (12.7)	1907 (13.1)	1456 (13.2)
	AC±AP	434 (44.4)	620 (40.1)	1158 (49.3)	1812 (56.7)	2517 (64.5)	2127 (59.9)	8234 (56.6)	6107 (55.5)

**Table 08: Treatment**  
**Full Analysis Dataset : ASIA**

	<b>Cohort 1 Retrospective (N=1001) (n %)</b>	<b>Cohort 1 Prospective (N=1581) (n %)</b>	<b>Cohort 2 (N=2357) (n %)</b>	<b>Cohort 3 (N=3206) (n %)</b>	<b>Cohort 4 (N=3973) (n %)</b>	<b>Cohort 5 (N=3596) (n %)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=14713)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=11117)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>								
Glycoprotein inhibitors	4 (0.4)	4 (0.3)	7 (0.3)	4 (0.1)	-		15 (0.1)	15 (0.1)
ADP receptor/P2Y12 inhibitors	121 (12.1)	175 (11.1)	276 (11.7)	362 (11.3)	366 (9.2)	355 (9.9)	1534 (10.4)	1179 (10.6)
Prostaglandin Cox inhibitors	4 (0.4)	5 (0.3)	8 (0.3)	8 (0.2)	14 (0.4)	14 (0.4)	49 (0.3)	35 (0.3)
ASA	100 (10.0)	161 (10.2)	12 (0.5)	224 (7.0)	181 (4.6)	183 (5.1)	761 (5.2)	578 (5.2)
	303 (30.3)	545 (34.5)	995 (42.2)	916 (28.6)	1063 (26.8)	989 (27.5)	4508 (30.6)	3519 (31.7)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>								
VKA	441 (44.1)	588 (37.2)	896 (38.0)	1035 (32.3)	1107 (27.9)	806 (22.4)	4432 (30.1)	3626 (32.6)
FXa	16 (1.6)	33 (2.1)	106 (4.5)	559 (17.4)	1253 (31.5)	1122 (31.2)	3073 (20.9)	1951 (17.5)
DTI	11 (1.1)	49 (3.1)	165 (7.0)	241 (7.5)	270 (6.8)	291 (8.1)	1016 (6.9)	725 (6.5)
Heparinoid	7 (0.7)	15 (0.9)	13 (0.6)	6 (0.2)	18 (0.5)	19 (0.5)	71 (0.5)	52 (0.5)
Heparins	8 (0.8)	29 (1.8)	119 (5.0)	192 (6.0)	139 (3.5)	215 (6.0)	694 (4.7)	479 (4.3)
Other	1 (0.1)	-	16 (0.7)	21 (0.7)	23 (0.6)	43 (1.2)	103 (0.7)	60 (0.5)

**Table 09 : Risk scores**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
CHADS2 Score	n (missing)	967 (34)	1552 (29)	2305 (52)	3150 (56)	3885 (88)	3524 (72)	14416 (297)	10892 (225)
	Mean (SD)	1.6 (1.1)	1.6 (1.1)	1.7 (1.1)	1.7 (1.1)	1.7 (1.1)	1.7 (1.2)	1.7 (1.1)	1.7 (1.1)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	967 (34)	1552 (29)	2305 (52)	3150 (56)	3885 (88)	3524 (72)	14416 (297)	10892 (225)
	0	102 (10.5)	206 (13.3)	225 (9.8)	377 (12.0)	483 (12.4)	504 (14.3)	1795 (12.5)	1291 (11.9)
	1	428 (44.3)	629 (40.5)	888 (38.5)	1137 (36.1)	1401 (36.1)	1193 (33.9)	5248 (36.4)	4055 (37.2)
	2	234 (24.2)	456 (29.4)	688 (29.8)	976 (31.0)	1184 (30.5)	1038 (29.5)	4342 (30.1)	3304 (30.3)
	3	132 (13.7)	181 (11.7)	319 (13.8)	450 (14.3)	527 (13.6)	514 (14.6)	1991 (13.8)	1477 (13.6)
	4	57 (5.9)	59 (3.8)	142 (6.2)	167 (5.3)	217 (5.6)	188 (5.3)	773 (5.4)	585 (5.4)
	5	12 (1.2)	18 (1.2)	37 (1.6)	40 (1.3)	65 (1.7)	76 (2.2)	236 (1.6)	160 (1.5)
	6	2 (0.2)	3 (0.2)	6 (0.3)	3 (0.1)	8 (0.2)	11 (0.3)	31 (0.2)	20 (0.2)
CHA2DS2- VASc Score	n (missing)	967 (34)	1552 (29)	2304 (53)	3138 (68)	3857 (116)	3468 (128)	14319 (394)	10851 (266)
	Mean (SD)	2.7 (1.6)	2.7 (1.5)	2.9 (1.6)	2.9 (1.6)	2.9 (1.6)	2.9 (1.7)	2.9 (1.6)	2.9 (1.6)
	Median (IQR)	3.0 (1.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	967 (34)	1552 (29)	2304 (53)	3138 (68)	3857 (116)	3468 (128)	14319 (394)	10851 (266)
	0	43 (4.4)	86 (5.5)	86 (3.7)	136 (4.3)	203 (5.3)	205 (5.9)	716 (5.0)	511 (4.7)
	1	214 (22.1)	288 (18.6)	409 (17.8)	501 (16.0)	571 (14.8)	558 (16.1)	2327 (16.3)	1769 (16.3)
	2	210 (21.7)	393 (25.3)	514 (22.3)	685 (21.8)	852 (22.1)	711 (20.5)	3155 (22.0)	2444 (22.5)
	3	211 (21.8)	333 (21.5)	505 (21.9)	742 (23.6)	901 (23.4)	751 (21.7)	3232 (22.6)	2481 (22.9)
	4	146 (15.1)	258 (16.6)	421 (18.3)	594 (18.9)	702 (18.2)	651 (18.8)	2626 (18.3)	1975 (18.2)

**Table 09 : Risk scores**  
**Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Retrospective patients (N=1001) (n %)	Cohort 1 Prospective patients (N=1581) (n %)	Cohort 2 (N=2357) (n %)	Cohort 3 (N=3206) (n %)	Cohort 4 (N=3973) (n %)	Cohort 5 (N=3596) (n %)	Total Prospective patients Cohorts 1 to 5 (N=14713)	Total Prospective patients Cohorts 1 to 4 (N=11117)
	5	97 (10.0)	136 (8.8)	224 (9.7)	294 (9.4)	389 (10.1)	355 (10.2)	1398 (9.8)	1043 (9.6)
	6-9	46 (4.8)	58 (3.7)	145 (6.3)	186 (5.9)	239 (6.2)	237 (6.8)	865 (6.0)	628 (5.8)
HAS-BLED score	n (missing)	602 (399)	1015 (566)	1535 (822)	2480 (726)	3183 (790)	2815 (781)	11028 (3685)	8213 (2904)
	Mean (SD)	1.5 (0.9)	1.5 (0.9)	1.5 (0.9)	1.3 (0.9)	1.3 (0.9)	1.3 (0.9)	1.3 (0.9)	1.4 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 5	0 to 4	0 to 4	0 to 5	0 to 5	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	602 (399)	1015 (566)	1535 (822)	2480 (726)	3183 (790)	2815 (781)	11028 (3685)	8213 (2904)
	0	79 (13.1)	120 (11.8)	185 (12.1)	431 (17.4)	601 (18.9)	550 (19.5)	1887 (17.1)	1337 (16.3)
	1	232 (38.5)	389 (38.3)	647 (42.1)	1071 (43.2)	1435 (45.1)	1255 (44.6)	4797 (43.5)	3542 (43.1)
	2	214 (35.5)	393 (38.7)	512 (33.4)	757 (30.5)	880 (27.6)	743 (26.4)	3285 (29.8)	2542 (31.0)
	3	62 (10.3)	91 (9.0)	171 (11.1)	186 (7.5)	220 (6.9)	239 (8.5)	907 (8.2)	668 (8.1)
	4	14 (2.3)	19 (1.9)	20 (1.3)	35 (1.4)	44 (1.4)	26 (0.9)	144 (1.3)	118 (1.4)
	5	1 (0.2)	3 (0.3)	-	-	3 (0.1)	2 (0.1)	8 (0.1)	6 (0.1)

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : ASIA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	9	20.9	5	11.6	-	-	-	-	-	-	-	-	24	55.8	5	11.6	-
	1	56	26.9	18	8.7	-	-	1	0.5	-	-	-	-	95	45.7	38	18.3	6
	2	69	33.3	22	10.6	-	-	-	-	-	-	2	1	75	36.2	39	18.8	3
	3	58	28.2	28	13.6	-	-	1	0.5	-	-	2	1	86	41.7	31	15	5
	4	49	33.6	24	16.4	-	-	-	-	-	-	-	-	54	37	19	13	-
	5	37	39.4	13	13.8	-	-	1	1.1	-	-	-	-	33	35.1	10	10.6	3
6-9	7	17.5	16	40	-	-	1	2.5	-	-	2	5	13	32.5	1	2.5	6	
Cohort 1 prospective	0	18	20.9	3	3.5	1	1.2	-	-	-	-	-	-	38	44.2	26	30.2	-
	1	77	27.2	28	9.9	1	0.4	1	0.4	4	1.4	3	1.1	123	43.5	46	16.3	5
	2	90	23.6	38	9.9	-	-	2	0.5	4	1	3	0.8	173	45.3	72	18.8	11
	3	73	22.2	41	12.5	-	-	5	1.5	3	0.9	4	1.2	142	43.2	61	18.5	4
	4	77	30.8	32	12.8	-	-	4	1.6	2	0.8	6	2.4	92	36.8	37	14.8	8
	5	40	30.8	17	13.1	-	-	1	0.8	2	1.5	4	3.1	51	39.2	15	11.5	6
6-9	12	21.1	12	21.1	-	-	1	1.8	2	3.5	2	3.5	20	35.1	8	14	1	
Cohort 2	0	13	15.1	10	11.6	1	1.2	-	-	8	9.3	-	-	34	39.5	20	23.3	-
	1	88	21.5	26	6.4	13	3.2	1	0.2	30	7.3	2	0.5	167	40.8	82	20	-
	2	138	27	45	8.8	19	3.7	1	0.2	35	6.8	4	0.8	191	37.3	79	15.4	2
	3	133	26.4	65	12.9	24	4.8	3	0.6	32	6.3	7	1.4	163	32.3	77	15.3	1
	4	121	28.9	72	17.2	17	4.1	8	1.9	12	2.9	8	1.9	128	30.5	53	12.6	2
	5	63	28.1	42	18.8	4	1.8	4	1.8	14	6.3	2	0.9	76	33.9	19	8.5	-
6-9	41	28.5	23	16	1	0.7	4	2.8	6	4.2	3	2.1	45	31.3	21	14.6	1	
Cohort 3	0	21	15.4	8	5.9	14	10.3	-	-	12	8.8	-	-	34	25	47	34.6	-
	1	78	15.7	33	6.6	76	15.3	-	-	30	6	2	0.4	146	29.3	133	26.7	3
	2	180	26.3	54	7.9	106	15.5	11	1.6	43	6.3	7	1	165	24.1	119	17.4	-
	3	185	25	66	8.9	127	17.2	16	2.2	47	6.4	11	1.5	182	24.6	105	14.2	3
4	147	24.8	63	10.6	93	15.7	22	3.7	35	5.9	13	2.2	147	24.8	73	12.3	1	

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : ASIA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	64	22	35	12	43	14.8	12	4.1	15	5.2	6	2.1	80	27.5	36	12.4	3
	6-9	46	25	26	14.1	18	9.8	7	3.8	10	5.4	1	0.5	71	38.6	5	2.7	2
Cohort 4	0	31	15.6	8	4	30	15.1	3	1.5	18	9	-	-	36	18.1	73	36.7	4
	1	108	19	22	3.9	136	23.9	12	2.1	39	6.9	4	0.7	123	21.6	125	22	2
	2	192	22.9	41	4.9	216	25.7	26	3.1	52	6.2	8	1	184	21.9	121	14.4	12
	3	185	21	70	7.9	278	31.6	36	4.1	48	5.4	12	1.4	149	16.9	103	11.7	20
	4	141	20.3	59	8.5	195	28.1	47	6.8	29	4.2	12	1.7	129	18.6	81	11.7	9
	5	74	19.5	39	10.3	96	25.3	35	9.2	8	2.1	5	1.3	84	22.2	38	10	10
	6-9	30	12.9	34	14.7	45	19.4	26	11.2	9	3.9	8	3.4	62	26.7	18	7.8	7
Cohort 5	0	23	11.3	10	4.9	32	15.7	-	-	15	7.4	-	-	37	18.1	87	42.6	1
	1	77	13.9	25	4.5	118	21.3	6	1.1	35	6.3	1	0.2	154	27.7	139	25	3
	2	117	16.6	43	6.1	173	24.5	18	2.6	64	9.1	13	1.8	158	22.4	119	16.9	6
	3	122	16.5	50	6.8	221	29.9	38	5.1	52	7	9	1.2	153	20.7	95	12.8	11
	4	94	14.7	42	6.6	199	31.1	41	6.4	39	6.1	5	0.8	137	21.4	83	13	11
	5	59	17	33	9.5	83	23.9	32	9.2	21	6.1	5	1.4	76	21.9	38	11	8
	6-9	26	11.1	25	10.7	49	20.9	38	16.2	8	3.4	5	2.1	65	27.8	18	7.7	3
Total Prospective patients Cohorts 1 to 5	0	106	14.9	39	5.5	78	11	3	0.4	53	7.5	-	-	179	25.2	253	35.6	5
	1	428	18.5	134	5.8	344	14.9	20	0.9	138	6	12	0.5	713	30.8	525	22.7	13
	2	717	23	221	7.1	514	16.5	58	1.9	198	6.3	35	1.1	871	27.9	510	16.3	31
	3	698	21.9	292	9.1	650	20.4	98	3.1	182	5.7	43	1.3	789	24.7	441	13.8	39
	4	580	22.4	268	10.3	504	19.4	122	4.7	117	4.5	44	1.7	633	24.4	327	12.6	31
	5	300	21.9	166	12.1	226	16.5	84	6.1	60	4.4	22	1.6	367	26.8	146	10.6	27
	6-9	155	18.2	120	14.1	113	13.3	76	8.9	35	4.1	19	2.2	263	30.9	70	8.2	14

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : ASIA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Total	0	83	16.4	29	5.7	46	9.1	3	0.6	38	7.5	-	-	142	28	166	32.7	4	
Prospective patients																			
Cohorts 1 to 4																			
	1	351	20	109	6.2	226	12.8	14	0.8	103	5.9	11	0.6	559	31.8	386	21.9	10	
	2	600	24.8	178	7.4	341	14.1	40	1.7	134	5.5	22	0.9	713	29.5	391	16.2	25	
	3	576	23.5	242	9.9	429	17.5	60	2.4	130	5.3	34	1.4	636	25.9	346	14.1	28	
	4	486	24.9	226	11.6	305	15.6	81	4.1	78	4	39	2	496	25.4	244	12.5	20	
	5	241	23.5	133	13	143	14	52	5.1	39	3.8	17	1.7	291	28.4	108	10.5	19	
	6-9	129	20.9	95	15.4	64	10.4	38	6.2	27	4.4	14	2.3	198	32.1	52	8.4	11	

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : ASIA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	
Cohort 1 retrospective	0	44	56.4	-	-	-	-	-	-	-	-	-	-	-	-	-	34	43.6	1
	1	95	41.5	16	7	-	-	1	0.4	-	-	1	0.4	77	33.6	39	17	3	
	2	37	17.7	33	15.8	-	-	1	0.5	-	-	2	1	124	59.3	12	5.7	5	
	3	3	5.5	20	36.4	-	-	2	3.6	-	-	3	5.5	27	49.1	-	-	7	
	4-9	-	-	9	64.3	-	-	-	-	-	-	-	-	5	35.7	-	-	1	
Cohort 1 prospective	0	70	59.8	-	-	1	0.9	-	-	2	1.7	-	-	-	-	44	37.6	3	
	1	117	30.8	25	6.6	-	-	2	0.5	6	1.6	6	1.6	153	40.3	71	18.7	9	
	2	48	12.5	56	14.6	-	-	6	1.6	4	1	9	2.3	242	63	19	4.9	9	
	3	8	9.4	20	23.5	-	-	3	3.5	1	1.2	5	5.9	42	49.4	6	7.1	6	
	4-9	1	5	4	20	-	-	1	5	-	-	1	5	12	60	1	5	2	
Cohort 2	0	79	42.7	-	-	12	6.5	-	-	24	13	-	-	-	-	70	37.8	-	
	1	191	29.6	33	5.1	39	6	1	0.2	73	11.3	2	0.3	193	29.9	114	17.6	1	
	2	91	17.9	77	15.1	17	3.3	1	0.2	17	3.3	16	3.1	249	48.9	41	8.1	3	
	3	14	8.2	41	24	3	1.8	7	4.1	3	1.8	4	2.3	94	55	5	2.9	-	
	4-9	1	5	7	35	-	-	2	10	-	-	-	-	10	50	-	-	-	
Cohort 3	0	138	32.2	-	-	83	19.3	-	-	44	10.3	-	-	-	-	164	38.2	2	
	1	299	28	67	6.3	220	20.6	7	0.7	85	8	10	0.9	196	18.4	182	17.1	5	
	2	104	13.8	110	14.6	89	11.8	37	4.9	33	4.4	18	2.4	315	41.8	48	6.4	3	
	3	25	13.4	33	17.7	13	7	9	4.8	3	1.6	4	2.2	85	45.7	14	7.5	-	
	4-9	1	2.9	4	11.4	3	8.6	3	8.6	-	-	1	2.9	22	62.9	1	2.9	-	
Cohort 4	0	184	31.1	-	-	165	27.9	-	-	60	10.2	-	-	-	-	182	30.8	10	
	1	319	22.7	64	4.6	495	35.3	25	1.8	81	5.8	13	0.9	202	14.4	204	14.5	32	
	2	105	12.1	120	13.8	143	16.5	86	9.9	18	2.1	16	1.8	314	36.1	67	7.7	11	
	3	15	6.9	30	13.9	22	10.2	31	14.4	3	1.4	11	5.1	91	42.1	13	6	4	
	4-9	1	2.2	12	26.1	2	4.3	7	15.2	-	-	2	4.3	20	43.5	2	4.3	1	

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : ASIA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
Cohort 5	0	112	20.7	-	-	147	27.1	-	-	80	14.8	-	-	-	-	203	37.5	8
	1	199	16.2	54	4.4	453	36.8	20	1.6	97	7.9	10	0.8	234	19	164	13.3	24
	2	63	8.6	80	10.9	122	16.7	78	10.7	26	3.6	18	2.5	285	38.9	60	8.2	11
	3	10	4.2	41	17.2	21	8.8	44	18.5	9	3.8	4	1.7	92	38.7	17	7.1	1
	4-9	2	7.1	5	17.9	1	3.6	7	25	1	3.6	-	-	12	42.9	-	-	-
Total Prospective patients Cohorts 1 to 5	0	583	31.3	-	-	408	21.9	-	-	210	11.3	-	-	-	-	663	35.6	23
Total Prospective patients Cohorts 1 to 4	1	1125	23.8	243	5.1	1207	25.5	55	1.2	342	7.2	41	0.9	978	20.7	735	15.6	71
	2	411	12.7	443	13.6	371	11.4	208	6.4	98	3	77	2.4	1405	43.3	235	7.2	37
	3	72	8	165	18.4	59	6.6	94	10.5	19	2.1	28	3.1	404	45.1	55	6.1	11
	4-9	6	4	32	21.5	6	4	20	13.4	1	0.7	4	2.7	76	51	4	2.7	3
	0	471	35.6	-	-	261	19.7	-	-	130	9.8	-	-	-	-	460	34.8	15
Total Prospective patients Cohorts 1 to 4	1	926	26.5	189	5.4	754	21.6	35	1	245	7	31	0.9	744	21.3	571	16.3	47
	2	348	13.8	363	14.4	249	9.9	130	5.2	72	2.9	59	2.3	1120	44.5	175	7	26
	3	62	9.4	124	18.8	38	5.8	50	7.6	10	1.5	24	3.6	312	47.4	38	5.8	10
	4-9	4	3.3	27	22.3	5	4.1	13	10.7	-	-	4	3.3	64	52.9	4	3.3	3
	0	471	35.6	-	-	261	19.7	-	-	130	9.8	-	-	-	-	460	34.8	15

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

Variable	Statistics	Cohort 1 Prospective patients (N=565) (n %)	Cohort 2 (N=893) (n %)	Cohort 3 (N=1027) (n %)	Cohort 4 (N=1059) (n %)	Total Prospective patients Cohorts 1 to 4 (N=3544)
TTR value, n(%)	n (missing)	320 (245)	536 (357)	558 (469)	485 (574)	1899 (1645)
	<65	277 (86.6)	450 (84.0)	463 (83.0)	391 (80.6)	1581 (83.3)
	>=65	43 (13.4)	86 (16.0)	95 (17.0)	94 (19.4)	318 (16.7)
TTR	n (missing)	320 (245)	536 (357)	558 (469)	485 (574)	1899 (1645)
	Mean (SD)	32.2 (27.3)	34.0 (27.8)	34.2 (28.0)	35.2 (29.5)	34.1 (28.2)
	Median (IQR)	28.3 (6.4 to 52.9)	31.1 (8.2 to 52.6)	31.7 (9.1 to 54.8)	31.6 (8.0 to 58.3)	31.0 (8.0 to 54.8)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	2431	4209	4774	3796	15210
	2-3	721 (29.7)	1345 (32.0)	1448 (30.3)	1230 (32.4)	4744 (31.2)
	<2	1481 (60.9)	2451 (58.2)	2907 (60.9)	2251 (59.3)	9090 (59.8)
	>3	229 (9.4)	413 (9.8)	419 (8.8)	315 (8.3)	1376 (9.0)
INR	n	2431	4209	4774	3796	15210
	Mean (SD)	2.0 (0.9)	2.0 (0.9)	2.0 (1.0)	2.0 (0.8)	2.0 (0.9)
	Median (IQR)	1.8 (1.4 to 2.3)	1.9 (1.4 to 2.4)	1.8 (1.4 to 2.3)	1.8 (1.4 to 2.3)	1.8 (1.4 to 2.3)
	Min to Max	0.9 to 15.5	0.8 to 12.2	0.8 to 18.6	0.8 to 12.2	0.8 to 18.6

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		11117	305	2.95	(2.64 to 3.30)
	<b>Cardiovascular death</b>	11117	106	1.03	(0.85 to 1.24)
	<b>Non-Cardiovascular death</b>	11117	109	1.05	(0.87 to 1.27)
	<b>Undetermined cause</b>	11117	90	0.87	(0.71 to 1.07)
Stroke/SE		11117	129	1.26	(1.06 to 1.49)
Major bleed		11117	50	0.49	(0.37 to 0.64)
Acute coronary syndrome		11117	43	0.42	(0.31 to 0.56)
Congestive Heart Failure		11117	119	1.16	(0.97 to 1.38)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

Outcome	Cause	ASIA		
		N	Events	%
<b>Cardiovascular causes</b>	Myocardial infarction	106	13	12.26
	Ischaemic stroke	106	8	7.55
	Congestive heart failure	106	42	39.62
	Sudden or unwitnessed death	106	16	15.09
	Other	106	27	25.47
<b>Non-cardiovascular causes</b>	Accidental / trauma	109	3	2.75
	Respiratory failure	109	21	19.27
	Infection/sepsis	109	21	19.27
	Malignancy	109	20	18.35
	Other	109	44	40.37

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :ASIA**

OUTCOME	ASIA		
	N	Events	%
Stroke(not including systemic embolism)	11117	125	1.12
Primary Ischemic Stroke	11117	81	0.73
<i>of which secondary hemorrhagic ischemic</i>	11117	7	0.06
<b>Primary intracerebral hemorrhage*</b>	11117	16	0.14
<i>Intracerebral</i>	11117	7	0.06
<i>Subarachnoid</i>	11117	4	0.04
<i>Intraventricular</i>	11117	1	0.01
<i>Subdural Hematoma</i>	11117	1	0.01
<i>Epidural Hematoma</i>	11117	1	0.01
Undetermined	11117	28	0.25

\*Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	511	464.00	6	1.29	(0.58 to 2.88)
1	1769	1640.68	19	1.16	(0.74 to 1.82)
2	2444	2294.64	39	1.70	(1.24 to 2.33)
3	2481	2322.83	64	2.76	(2.16 to 3.52)
4+	3646	3372.73	170	5.04	(4.34 to 5.86)
Unknown	266	245.42	7	2.85	(1.36 to 5.98)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	511	464.00	0	-	-
1	1769	1636.03	7	0.43	(0.20 to 0.90)
2	2444	2282.56	23	1.01	(0.67 to 1.52)
3	2481	2308.37	31	1.34	(0.94 to 1.91)
4+	3646	3344.73	65	1.94	(1.52 to 2.48)
Unknown	266	243.89	3	1.23	(0.40 to 3.81)

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : ASIA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	511	464.00	0	-	-
1	1769	1640.13	2	0.12	(0.03 to 0.49)
2	2444	2293.44	5	0.22	(0.09 to 0.52)
3	2481	2311.02	20	0.87	(0.56 to 1.34)
4+	3646	3362.88	23	0.68	(0.45 to 1.03)
Unknown	266	245.42	0	-	-